BLOOD TUMOR MARKERS FOR MOLECULAR DIAGNOSIS OF BREAST DISEASE AND MONITORING

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 乳腺癌是女性最常见的癌症，占所有女性癌症的三分之一。乳腺癌的死亡通常是由于扩散到其他器官，这可能通过血液发生。我们设计了一种血液检测，使用一种名为K19 RT-PCR的测试来检测少量从乳房逃脱的乳腺癌细胞。对乳腺癌女性的初步测试表明，血液中癌细胞的高K19mRNA水平与更晚期的癌症有关。我们还看到，在化疗后，这些K19水平下降到正常水平。我们认为，血液中癌细胞的存在与癌症复发有关，K19基因的高表达与肿瘤的复发有关，K19基因高表达的肿瘤较大。 为了验证这一假设，我们将收集最近诊断为乳腺癌的患者以及良性乳腺疾病患者的血液样本。在测量K19mRNA之后，我们将比较不同组的平均K19水平。对于乳腺癌患者，我们还会将K19水平与已知与医学进步相关的肿瘤特征进行比较。然后将随着时间的推移跟踪K19水平，以评估癌症治疗期间的趋势，看看它们是否与肿瘤反应、复发和生存有关。受试者样本还将用于开发乳腺癌的其他早期标记，例如一种名为BI-PAP-A(S.Sommer)和蛋白质组学分析(T.Lee)的新型核酸分析。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Breast cancer is the most common cancer in women, accounting for a third of all female cancers. Death from breast cancer is usually due to spread to other organs, which can occur through the blood. We have designed a blood test to detect small numbers of breast cancer cells that have escaped the breast, using a test called K19 RT-PCR. Initial testing in women with breast cancer suggests that high K19 mRNA levels from cancer cells in the blood relate to more advanced cancer. We have also seen that these K19 levels go down to normal levels after treatment with chemotherapy. We believe that the presence of cancer cells in the blood indicated by higher K19 mRNA will be associated with cancer recurrence, and that higher K19 will be found with bigger tumors. To test this hypothesis, we will collect blood samples from patients recently diagnosed with breast cancer, as well as from those with benign breast disease. After measuring K19 mRNA, we will compare average K19 levels across the groups. For those with breast cancer, we will also compare K19 levels to tumor characteristics known to be associated with medical progress. K19 levels will then be followed over time to evaluate trends during cancer treatment, to see if they relate to tumor response, relapse and survival. Subject sample will also be used to develop other early markers of breast cancer, such as a novel nucleic acid assay called BI-PAP-A (S. Sommer) and proteomic profiling (T. Lee).